Inhibition of interferon γ signaling by the short chain fatty acid butyrate

Molecular Cancer Research

Volumn 1, Issue 11, 2003, Pages 855-862

  Klampfer, Lidija ^a   Huang, Jie ^a   Sasazuki, Takehiko ^b   Shirasawa, Senji ^b   Augenlicht, Leonard ^a  

^a MONTEFIORE MEDICAL CENTER   (United States)

^b NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BUTYRIC ACID; CYTOKINE; GAMMA INTERFERON; JANUS KINASE; JANUS KINASE 2; SERINE; SHORT CHAIN FATTY ACID; STAT1 PROTEIN; TRANSCRIPTION FACTOR; TYROSINE; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL DIFFERENTIATION; CELL NUCLEUS; CELL PROLIFERATION; CELL SURVIVAL; COLON MUCOSA; CONTROLLED STUDY; CROHN DISEASE; CYTOKINE RELEASE; DNA BINDING; ENTERITIS; GAMMA ACTIVATED SEQUENCE SITE; GENE CONSTRUCT; GENE SEQUENCE; HUMAN; HUMAN CELL; INFLAMMATION; LAMINA PROPRIA; MUCOSA INFLAMMATION; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN TRANSPORT; REGULATORY MECHANISM; REPORTER GENE; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; ULCERATIVE COLITIS;

BUTYRATES; CELL LINE, TUMOR; CELL NUCLEUS; DNA; DNA-BINDING PROTEINS; ENZYME ACTIVATION; GENE EXPRESSION REGULATION; HUMANS; INTERFERON TYPE II; JANUS KINASE 2; PHOSPHORYLATION; PHOSPHOSERINE; PHOSPHOTYROSINE; PROTEIN TRANSPORT; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; SIGNAL TRANSDUCTION; STAT1 TRANSCRIPTION FACTOR; TRANS-ACTIVATORS; TRANSCRIPTION, GENETIC; TRANSFECTION;

JANUS;

EID: 0141653817     PISSN: 15417786     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (68)

1. von Engelhardt, W., Bartels, J., Kirschberger, S., Meyer zu Duttingdorf, H. D., and Busche, R. Role of short-chain fatty acids in the hind gut. Vet. Q., 20: S52-S59, 1998.
2. Augenlicht, L. H., Mariadason, J. M., Wilson, A., Arango, D., Yang, W., Heerdt, B. G., and Velcich, A. Short chain fatty acids and colon cancer. J. Nutr., 132: 3804S-3808S, 2002.
3. Luciano, L., Hass, R., Busche, R., von Engelhardt, W., and Reale, E. Withdrawal of butyrate from the colonic mucosa triggers "mass apoptosis" primarily in the G0/G1 phase of the cell cycle. Cell Tissue Res., 286: 81-92, 1996.
4. Archer, S., Meng, S., Wu, J., Johnson, J., Tang, R., and Hodin, R. Butyrate inhibits colon carcinoma cell growth through two distinct pathways. Surgery, 124: 248-253, 1998.
5. Clarke, K. O., Feinman, R., and Harrison, L. E. Tributyrin, an oral butyrate analogue, induces apoptosis through the activation of caspase-3. Cancer Lett., 171: 57-65, 2001.
6. Litvak, D. A., Hwang, K. O., Evers, B. M., and Townsend, C. M., Jr. Induction of apoptosis in human gastric cancer by sodium butyrate. Anticancer Res., 20: 779-784, 2000.
7. Heerdt, B. G., Houston, M. A., and Augenlicht, L. H. Short-chain fatty acid-initiated cell cycle arrest and apoptosis of colonic epithelial cells is linked to mitochondrial function. Cell Growth & Differ., 8: 523-532, 1997.
8. Heerdt, B. G., Houston, M. A., and Augenlicht, L. H. Potentiation by specific short-chain fatty acids of differentiation and apoptosis in human colonic carcinoma cell lines. Cancer Res., 54: 3288-3293, 1994.
9. Inan, M. S., Rasoulpour, R. J., Yin, L., Hubbard, A. K., Rosenberg, D. W., and Giardina, C. The luminal short-chain fatty acid butyrate modulates NF-κB activity in a human colonic epithelial cell line. Gastroenterology, 118: 724-734, 2000.
10. Luhrs, H., Gerke, T., Muller, J. G., Melcher, R., Schauber, J., Boxberge, F., Scheppach, W., and Menzel, T. Butyrate inhibits NF-κB activation in lamina propria macrophages of patients with ulcerative colitis. Scand. J. Gastroenterol., 37: 458-466, 2002.
11. Luhrs, H., Kudlich, T., Neumann, M., Schauber, J., Melcher, R., Gostner, A., Scheppach, W., and Menzel, T. P. Butyrate-enhanced TNFα-induced apoptosis is associated with inhibition of NF-κB. Anticancer Res., 22: 1561-1568, 2002.
12. Segain, J. P., Raingeard de la Bletiere, D., Bourreille, A., Leray, V., Gervois, N., Rosales, C., Ferrier, L., Bonnet, C., Blottiere, H. M., and Galmiche, J. P. Butyrate inhibits inflammatory responses through NFκB inhibition: implications for Crohn's disease. Gut, 47: 397-403, 2000.
13. Yin, L., Laevsky, G., and Giardina, C. Butyrate suppression of colonocyte NF-κB activation and cellular proteasome activity. J. Biol. Chem., 276: 44641-44646, 2001.
14. Pahl, H. L. Activators and target genes of Rel/NF-κB transcription factors. Oncogene, 18: 6853-6866, 1999.
15. Shao, J., Fujiwara, T., Kadowaki, Y., Fukazawa, T., Waku, T., Itoshima, T., Yamatsuji, T., Nishizaki, M., Roth, J. A., and Tanaka, N. Overexpression of the wild-type p53 gene inhibits NF-κB activity and synergizes with aspirin to induce apoptosis in human colon cancer cells. Oncogene, 19: 726-736, 2000.
16. Lind, D. S., Hochwald, S. N., Malaty, J., Rekkas, S., Hebig, P., Mishra, G., Moldawer, L. L., Copeland, E. M., 3rd, and Mackay, S. Nuclear factor-κB is upregulated in colorectal cancer. Surgery, 130: 363-369, 2001.
17. Rogler, G., Brand, K., Vogl, D., Page, S., Hofmeister, R., Andus, T., Knuechel, R., Baeuerle, P. A., Scholmerich, J., and Gross, V. Nuclear factor κB is activated in macrophages and epithelial cells of inflamed intestinal mucosa. Gastroenterology, 115: 357-369, 1998.
18. Schreiber, S., Nikolaus, S., and Hampe, J. Activation of nuclear factor κB in inflammatory bowel disease. Gut, 42: 477-484, 1998.
19. Butzner, J. D., Parmar, R., Bell, C. J., and Dalal, V. Butyrate enema therapy stimulates mucosal repair in experimental colitis in the rat. Gut, 38: 568-573, 1996.
20. Kopp, E. and Ghosh, S. Inhibition of NF-κB by sodium salicylate and aspirin. Science, 265: 956-959, 1994.
21. McDade, T. P., Perugini, R. A., Vittimberga, F. J., Jr., Carrigan, R. C., and Callery, M. P. Salicylates inhibit NF-κB FB activation and enhance TNF-α-induced apoptosis in human pancreatic cancer cells. J. Surg. Res., 83: 56-61, 1999.
22. Scheppach, W., Sommer, H., Kirchner, T., Paganelli, G. M., Bartram, P., Christl, S., Richter, F., Dusel, G., and Kasper, H. Effect of butyrate enemas on the colonic mucosa in distal ulcerative colitis. Gastroenterology, 103: 51-56, 1992.
23. Scheppach, W., Christl, S. U., Bartram, H. P., Richter, F., and Kasper, H. Effects of short-chain fatty acids on the inflamed colonic mucosa. Scand. J. Gastroenterol. Suppl., 222: 53-57, 1997.
24. Yamamoto, Y. and Gaynor, R. B. Therapeutic potential of inhibition of the NF-κB pathway in the treatment of inflammation and cancer. J. Clin. Invest., 107: 135-142, 2001.
25. Yamamoto, Y., Yin, M. J., Lin, K. M., and Gaynor, R. B. Sulindac inhibits activation of the NF-κB pathway. J. Biol. Chem., 274: 27307-27314, 1999.
26. Breese, E., Braegger, C. P., Corrigan, C. J., Walker-Smith, J. A., and MacDonald, T. T. Interleukin-2- and interferon-γ-secreting T cells in normal and diseased human intestinal mucosa. Immunology, 78: 127-131, 1993.
27. Fais, S., Capobianchi, M. R., Pallone, F., Di Marco, P., Boirivant, M., Dianzani, F., and Torsoli, A. Spontaneous release of interferon γ by intestinal lamina propria lymphocytes in Crohn's disease. Kinetics of in vitro response to interferon γ inducers. Gut, 32: 403-407, 1991.
28. Fuss, I. J., Neurath, M., Boirivant, M., Klein, J. S., de la Motte, C., Strong, S. A., Fiocchi, C., and Strober, W. Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-γ, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J. Immunol., 157: 1261-1270, 1996.
29. Stallmach, A., Schafer, F., Hoffmann, S., Weber, S., Muller-Molaian, I., Schneider, T., Kohne, G., Ecker, K. W., Feifel, G., and Zeitz, M. Increased state of activation of CD4 positive T cells and elevated interferon γ production in pouchitis. Gut, 43: 499-505, 1998.
30. Darnell, J. E., Jr., Kerr, I. M., and Stark, G. R. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science, 264: 1415-1421, 1994.
31. Decker, T. and Kovarik, P. Serine phosphorylation of STATs. Oncogene, 19: 2628-2637, 2000.
32. Jove, R. Preface: STAT signaling. Oncogene, 19: 2466-2467, 2000.
33. Suzuki, A., Hanada, T., Mitsuyama, K., Yoshida, T., Kamizono, S., Hoshino, T., Kubo, M., Yamashita, A., Okabe, M., Takeda, K., Akira, S., Matsumoto, S., Toyonaga, A., Sata, M., and Yoshimura, A. CIS3/SOCS3/SS13 plays a negative regulatory role in STAT3 activation and intestinal inflammation. J. Exp. Med., 193: 471-481, 2001.
34. Schreiber, S., Rosenstiel, P., Hampe, J., Nikolaus, S., Groessner, B., Schottelius, A., Kuhbacher, T., Hamling, J., Folsch, U. R., and Seegert, D. Activation of signal transducer and activator of transcription (STAT) 1 in human chronic inflammatory bowel disease. Gut, 51: 379-385, 2002.
35. Kuhbacher, T., Gionchetti, P., Hampe, J., Helwig, U., Rosenstiel, P., Campieri, M., Buhr, H. J., and Schreiber, S. Activation of signal-transducer and activator of transcription 1 (STAT1) in pouchitis. Clin. Exp. Immunol., 123: 395-401, 2001.
36. Abril, E., Real, L. M., Serrano, A., Jimenez, P., Garcia, A., Canton, J., Trigo, I., Garrido, F., and Ruiz-Cabello, F. Unresponsiveness to interferon associated with STAT1 protein deficiency in a gastric adenocarcinoma cell line. Cancer Immunol. Immunother., 47: 113-120, 1998.
37. Clifford, J. L., Walch, E., Yang, X., Xu, X., Alberts, D. S., Clayman, G. L., El-Naggar, A. K., Lotan, R., and Lippman, S. M. Suppression of type I interferon signaling proteins is an early event in squamous skin carcinogenesis. Clin. Cancer Res., 8: 2067-2072, 2002.
38. Shou, J., Soriano, R., Hayward, S. W., Cunha, G. R., Williams, P. M., and Gao, W. Q. Expression profiling of a human cell line model of prostatic cancer reveals a direct involvement of interferon signaling in prostate tumor progression. Proc. Natl. Acad. Sci. USA, 99: 2830-2835, 2002.
39. Bowman, T., Garcia, R., Turkson, J., and Jove, R. STATs in oncogenesis. Oncogene, 19: 2474-2488, 2000.
40. Frank, D. A. and Varticovski, L. BCR/abl leads to the constitutive activation of Stat proteins, and shares an epitope with tyrosine phosphorylated Stats. Leukemia, 10: 1724-1730, 1996.
41. Magrassi, L., De-Fraja, C., Conti, L., Butti, G., Infuso, L., Govoni, S., and Cattaneo, E. Expression of the JAK and STAT superfamilies in human meningiomas. J. Neurosurg., 91: 440-446, 1999.
42. Watson, C. J. and Miller, W. R. Elevated levels of members of the STAT family of transcription factors in breast carcinoma nuclear extracts. Br. J. Cancer, 71: 840-844, 1995.
43. Ullman, T. A. Cancer in inflammatory bowel disease. Curr. Treat. Options Gastroenterol., 5: 163-171, 2002.
44. Biasco, G., Rossini, F. P., Hakim, R., Brandi, G., Di Battista, M., Di Febo, G., Calabrese, C., Santucci, R., and Miglioli, M. Cancer surveillance in ulcerative colitis: critical analysis of long-term prospective programme. Dig. Liver Dis., 34: 339-342, 2002.
45. Shirasawa, S., Furuse, M., Yokoyama, N., and Sasazuki, T. Altered growth of human colon cancer cell lines disrupted at activated Ki-ras. Science, 260: 85-88, 1993.
46. Cummings, J. H., Pomare, E. W., Branch, W. J., Naylor, C. P., and Macfarlane, G. T. Short chain fatty acids in human large intestine, portal, hepatic and venous blood. Gut, 28: 1221-1227, 1987.
47. Gresser, I. Biologic effects of interferons. J. Invest. Dermatol., 95. 66S-71S, 1990.
48. Vilcek, J. Interferon, Science, 168: 398-399, 1970.
49. Sen, G. C. Novel functions of interferon-induced proteins. Semin. Cancer Biol., 10: 93-101, 2000.
50. Christ, A. D., Stevens, A. C., Koeppen, H., Walsh, S., Omata, F., Devergne, O., Birkenbach, M., and Blumberg, R. S. An interleukin 12-related cytokine is upregulated in ulcerative colitis but not in Crohn's disease. Gastroenterology, 115: 307-313, 1998.
51. Turkson, J. and Jove, R. STAT proteins: novel molecular targets for cancer drug discovery. Oncogene, 19: 6613-6626, 2000.
52. Scheppach, W. Treatment of distal ulcerative colitis with short-chain fatty acid enemas. A placebo-controlled trial. German-Austrian SCFA Study Group. Dig. Dis. Sci., 41: 2254-2259, 1996.
53. Wahl, S. M. Transforming growth factor β: the good, the bad, and the ugly. J. Exp. Med., 180: 1587-1590, 1994.
54. Monteleone, G., Kumberova, A., Croft, N. M., McKenzie, C., Steer, H. W., and MacDonald, T. T. Blocking Smad7 restores TGF-β1 signaling in chronic inflammatory bowel disease. J. Clin. Invest., 108: 601-609, 2001.
55. Ulloa, L., Doody, J., and Massague, J. Inhibition of transforming growth factor-β/SMAD signalling by the interferon-γ/STAT pathway. Nature, 397: 710-713, 1999.
56. Fiocchi, C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology, 115: 182-205, 1998.
57. Podolsky, D. K. Inflammatory bowel disease (1). N. Engl. J. Med., 325: 928-937, 1991.
58. Podolsky, D. K. Inflammatory bowel disease (2). N. Engl. J. Med., 325: 1008-1016, 1991.
59. Hisamatsu, T., Watanabe, M., Ogata, H., Ezaki, T., Hozawa, S., Ishii, H., Kanai, T., and Hibi, T. Interferon-inducible gene family 1-8U expression in colitis-associated colon cancer and severely inflamed mucosa in ulcerative colitis. Cancer Res., 59: 5927-5931, 1999.
60. Paulukat, J., Bosmann, M., Nold, M., Garkisch, S., Kampfer, H., Frank, S., Raedle, J., Zeuzem, S., Pfeilschiffer, J., and Muhl, H. Expression and release of IL-18 binding protein in response to IFN-γ. J. Immunol., 167: 7038-7043, 2001.
61. Cao, R., Farnebo, J., Kurimoto, M., and Cao, Y. Interleukin-18 acts as an angiogenesis and tumor suppressor. FASEB J., 13: 2195-2202, 1999.
62. Dinarello, C. A. Interleukin-18, a proinflammatory cytokine. Eur. Cytokine Netw., 11: 483-486, 2000.
63. Dinarello, C. A. Targeting interleukin 18 with interleukin 18 binding protein. Ann. Rheum. Dis., 59 (Suppl. 1): 117-120, 2000.
64. Mariadason, J. M., Comer, G. A., and Augenlicht, L. H. Genetic reprogramming in pathways of colonic cell maturation induced by short chain fatty acids: comparison with trichostatin A, sulindac, and curcumin and implications for chemoprevention of colon cancer. Cancer Res., 60: 4561-4572, 2000.
65. Nikitakis, N. G., Hamburger, A. W., and Sauk, J. J. The nonsteroidal anti-inflammatory drug sulindac causes down-regulation of signal transducer and activator of transcription 3 in human oral squamous cell carcinoma cells. Cancer Res., 62: 1004-1007, 2002.
66. Roberts, R. B., Min, L., Washington, M. K., Olsen, S. J., Settle, S. H., Coffey, R. J., and Threadgill, D. W. Importance of epidermal growth factor receptor signaling in establishment of adenomas and maintenance of carcinomas during intestinal tumorigenesis. Proc. Natl. Acad. Sci. USA, 99: 1521-1526, 2002,
67. Malecka-Panas, E., Kordek, R., Biernat, W., Tureaud, J., Liberski, P. P., and Majumdar, A. P. Differential activation of total and EGF receptor (EGF-R) tyrosine kinase (tyr-k) in the rectal mucosa in patients with adenomatous polyps, ulcerative colitis and colon cancer. Hepatogastroenterology, 44: 435-440, 1997.
68. Pai, R., Soreghan, B., Szabo, I. L., Pavelka, M., Baatar, D., and Tarnawski, A. S. Prostaglandin E2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat. Med., 8: 289-293, 2002.